IL117518A - The use of the product of aminotterlin to prepare a drug for the treatment of cardiovascular disease - Google Patents
The use of the product of aminotterlin to prepare a drug for the treatment of cardiovascular diseaseInfo
- Publication number
- IL117518A IL117518A IL11751896A IL11751896A IL117518A IL 117518 A IL117518 A IL 117518A IL 11751896 A IL11751896 A IL 11751896A IL 11751896 A IL11751896 A IL 11751896A IL 117518 A IL117518 A IL 117518A
- Authority
- IL
- Israel
- Prior art keywords
- chf
- pharmaceutical compositions
- treatment
- preparation
- heart failure
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 238000011282 treatment Methods 0.000 title claims description 8
- JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical class C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 title description 4
- 208000024172 Cardiovascular disease Diseases 0.000 title description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims abstract description 18
- 206010019280 Heart failures Diseases 0.000 claims abstract description 18
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 15
- 208000019622 heart disease Diseases 0.000 claims abstract description 6
- OMMYLOLVPCCZQZ-UHFFFAOYSA-N [6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate Chemical compound C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1CC(NC)CC2 OMMYLOLVPCCZQZ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 208000020446 Cardiac disease Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 31
- TWTMQRXNAZGSCE-UHFFFAOYSA-N hydron;[6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate;chloride Chemical compound Cl.C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1CC(NC)CC2 TWTMQRXNAZGSCE-UHFFFAOYSA-N 0.000 description 31
- 230000000694 effects Effects 0.000 description 20
- MIMDMPWWTWVHFK-UHFFFAOYSA-N 6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol;hydrochloride Chemical compound Cl.C1=CC(O)=C(O)C2=C1CC(NC)CC2 MIMDMPWWTWVHFK-UHFFFAOYSA-N 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 19
- 229960003638 dopamine Drugs 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 239000003814 drug Substances 0.000 description 12
- 230000003291 dopaminomimetic effect Effects 0.000 description 10
- 230000000004 hemodynamic effect Effects 0.000 description 8
- 230000002093 peripheral effect Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 239000002934 diuretic Substances 0.000 description 6
- 229940030606 diuretics Drugs 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000002182 neurohumoral effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 4
- 206010037368 Pulmonary congestion Diseases 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 4
- 230000001077 hypotensive effect Effects 0.000 description 4
- 230000003518 presynaptic effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 3
- 108060003345 Adrenergic Receptor Proteins 0.000 description 3
- 102000017910 Adrenergic receptor Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940102884 adrenalin Drugs 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 150000003943 catecholamines Chemical class 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 208000027744 congestion Diseases 0.000 description 3
- 208000021822 hypotensive Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- -1 isobutyroyloxy-2-methylaminotetralin Chemical compound 0.000 description 3
- 230000036513 peripheral conductance Effects 0.000 description 3
- 230000036581 peripheral resistance Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000000304 vasodilatating effect Effects 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 230000036586 afterload Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 210000001177 vas deferen Anatomy 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- BHDFPNRSDABMPW-UHFFFAOYSA-N 6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol Chemical compound C1=CC(O)=C(O)C2=C1CC(NC)CC2 BHDFPNRSDABMPW-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010050394 Hyperkaliuria Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002562 anti-bronchospastic effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000035874 hyperreactivity Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000036230 kaliuresis Effects 0.000 description 1
- 229960004145 levosulpiride Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002563 splenic artery Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 230000008700 sympathetic activation Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL13541600A IL135416A0 (en) | 1995-03-17 | 2000-04-02 | The use of an aminotetralin derivative in the preparation of pharmaceutical compositions for the treatment of cardiovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT95MI000532A IT1275935B1 (it) | 1995-03-17 | 1995-03-17 | Derivato di aminotetralina per la terapia di malattie cardiovascolari |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL117518A0 IL117518A0 (en) | 1996-07-23 |
| IL117518A true IL117518A (en) | 2001-05-20 |
Family
ID=11370947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11751896A IL117518A (en) | 1995-03-17 | 1996-03-17 | The use of the product of aminotterlin to prepare a drug for the treatment of cardiovascular disease |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US6013678A (ru) |
| EP (2) | EP0814791B1 (ru) |
| JP (1) | JPH11502211A (ru) |
| KR (1) | KR100391143B1 (ru) |
| CN (1) | CN1112920C (ru) |
| AT (1) | ATE218856T1 (ru) |
| AU (1) | AU702656B2 (ru) |
| BR (1) | BR9607996A (ru) |
| CA (1) | CA2215671A1 (ru) |
| CZ (1) | CZ288488B6 (ru) |
| DE (1) | DE69621786T2 (ru) |
| DK (1) | DK0814791T3 (ru) |
| EA (1) | EA000937B1 (ru) |
| EE (1) | EE04040B1 (ru) |
| ES (1) | ES2177769T3 (ru) |
| HK (2) | HK1004802A1 (ru) |
| HU (1) | HUP9801686A3 (ru) |
| IL (1) | IL117518A (ru) |
| IT (1) | IT1275935B1 (ru) |
| LT (1) | LT4355B (ru) |
| LV (1) | LV11882B (ru) |
| MX (1) | MX9706971A (ru) |
| NO (1) | NO317402B1 (ru) |
| NZ (1) | NZ303993A (ru) |
| PL (1) | PL183347B1 (ru) |
| PT (1) | PT814791E (ru) |
| SI (1) | SI9620036B (ru) |
| SK (1) | SK282952B6 (ru) |
| TR (1) | TR199700963T1 (ru) |
| WO (1) | WO1996029065A2 (ru) |
| ZA (1) | ZA962073B (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2695157B2 (ja) * | 1986-12-29 | 1997-12-24 | 松下電器産業株式会社 | 可変パイプラインプロセッサ |
| WO2000076544A1 (en) * | 1996-03-13 | 2000-12-21 | Chiesi Farmaceutici S.P.A. | Aminotetralin derivative for the therapy of cardiovascular diseases |
| SI1183046T1 (en) * | 1999-06-09 | 2004-02-29 | Chiesi Farmaceutici S.P.A. | Aminotetralin derivative for the therapy of cardiovascular diseases |
| MXPA01012638A (es) * | 1999-06-09 | 2002-07-22 | Chiesi Farma Spa | Derivados de aminotetralina para la terapia de enfermedades cardiovasculares. |
| IT1313583B1 (it) * | 1999-07-30 | 2002-09-09 | Chiesi Farma Spa | Derivati 2-amminotetralinici per la terapia del glaucoma. |
| IL152751A0 (en) * | 2000-05-12 | 2003-06-24 | Chiesi Farma Spa | Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them |
| SE0101854L (sv) * | 2001-05-28 | 2002-11-29 | Bioneris Ab | Användning av en förening med en negativt laddad region av grupper för behandling av restenos. |
| EP1384708A1 (en) * | 2002-07-26 | 2004-01-28 | CHIESI FARMACEUTICI S.p.A. | Process for the manufacture of form I of nolomirole hydrochloride |
| US20050101668A1 (en) * | 2003-07-24 | 2005-05-12 | Chiesi Farmaceutici S.P.A. | Aminotetralin derivatives as a medicament for the treatment and prevention of myocardial ischemic conditions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4134997A (en) * | 1977-03-01 | 1979-01-16 | University Of Iowa Research Foundation | Effect of an aminotetralin derivative on coronary blood flow in infarcted hearts |
| SU998342A1 (ru) | 1981-12-11 | 1983-02-23 | Предприятие П/Я А-3732 | Способ получени синтетического цеолита типа @ |
| IT1218322B (it) * | 1982-06-10 | 1990-04-12 | Chiesi Farma Spa | Derivati di 1,2,3,4-tetraidronaftalene,procedimento di preparazione e relative composizioni farmaceutiche |
-
1995
- 1995-03-17 IT IT95MI000532A patent/IT1275935B1/it active IP Right Grant
-
1996
- 1996-03-13 CZ CZ19972866A patent/CZ288488B6/cs not_active IP Right Cessation
- 1996-03-13 EA EA199700243A patent/EA000937B1/ru not_active IP Right Cessation
- 1996-03-13 NZ NZ303993A patent/NZ303993A/xx unknown
- 1996-03-13 PT PT96907446T patent/PT814791E/pt unknown
- 1996-03-13 BR BR9607996A patent/BR9607996A/pt not_active Application Discontinuation
- 1996-03-13 HU HU9801686A patent/HUP9801686A3/hu unknown
- 1996-03-13 EP EP96907446A patent/EP0814791B1/en not_active Expired - Lifetime
- 1996-03-13 AU AU51072/96A patent/AU702656B2/en not_active Ceased
- 1996-03-13 DK DK96907446T patent/DK0814791T3/da active
- 1996-03-13 EE EE9700231A patent/EE04040B1/xx not_active IP Right Cessation
- 1996-03-13 CA CA002215671A patent/CA2215671A1/en not_active Abandoned
- 1996-03-13 KR KR1019970706438A patent/KR100391143B1/ko not_active IP Right Cessation
- 1996-03-13 EP EP02001772A patent/EP1216702A3/en not_active Withdrawn
- 1996-03-13 ES ES96907446T patent/ES2177769T3/es not_active Expired - Lifetime
- 1996-03-13 MX MX9706971A patent/MX9706971A/es not_active IP Right Cessation
- 1996-03-13 PL PL96322284A patent/PL183347B1/pl not_active IP Right Cessation
- 1996-03-13 JP JP8528045A patent/JPH11502211A/ja not_active Ceased
- 1996-03-13 TR TR97/00963T patent/TR199700963T1/xx unknown
- 1996-03-13 CN CN96193312A patent/CN1112920C/zh not_active Expired - Fee Related
- 1996-03-13 SK SK1254-97A patent/SK282952B6/sk unknown
- 1996-03-13 SI SI9620036A patent/SI9620036B/sl not_active IP Right Cessation
- 1996-03-13 WO PCT/EP1996/001060 patent/WO1996029065A2/en not_active Application Discontinuation
- 1996-03-13 US US08/913,363 patent/US6013678A/en not_active Expired - Fee Related
- 1996-03-13 AT AT96907446T patent/ATE218856T1/de not_active IP Right Cessation
- 1996-03-13 DE DE69621786T patent/DE69621786T2/de not_active Expired - Fee Related
- 1996-03-14 ZA ZA962073A patent/ZA962073B/xx unknown
- 1996-03-17 IL IL11751896A patent/IL117518A/en not_active IP Right Cessation
-
1997
- 1997-09-15 LT LT97-147A patent/LT4355B/lt not_active IP Right Cessation
- 1997-09-15 LV LVP-97-166A patent/LV11882B/en unknown
- 1997-09-16 NO NO19974267A patent/NO317402B1/no not_active IP Right Cessation
-
1998
- 1998-05-12 HK HK98104093A patent/HK1004802A1/xx not_active IP Right Cessation
-
1999
- 1999-06-09 US US09/328,434 patent/US6103760A/en not_active Expired - Fee Related
-
2002
- 2002-12-19 HK HK02109206.9A patent/HK1048060A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080287344A1 (en) | Use of Amino Acids for Making Medicines for Treating Insulin Resistance | |
| EP0814791B1 (en) | Aminotetralin derivative for the therapy of cardiovascular diseases | |
| Om | Cardiovascular complications of cocaine | |
| AU766230B2 (en) | Aminotetralin derivative for the therapy of cardiovascular diseases | |
| Nademanee | Cardiovascular effects and toxicities of cocaine | |
| Aronson et al. | Effects of fenoldopam on renal blood flow and systemic hemodynamics during isoilurane anesthesia | |
| WO2000076544A1 (en) | Aminotetralin derivative for the therapy of cardiovascular diseases | |
| JP2001507006A (ja) | 糖尿病性血管機能不全の予防のための薬剤の製造へのｃｏｍｔ阻害剤の使用 | |
| EP1331004A2 (en) | Aminotetralin Derivative for the Therapy of Cardiovascular Diseases | |
| Bevan et al. | P. Fernyhough, LT Diemel, WJ Smith & DR Tomlinson, Department of Pharmacology, Queen Mary and Westfield College, Mile End Road, London El 4NS. Neuropeptide gene expression in sensoryneurones is regulated by the classic neurotrophic factor, nerve growth factor (NGF). | |
| Bevan et al. | P. Fernyhough, LT Diemel, WJ Smith & DR Tomlinson, Department of Pharmacology, Queen Mary and Westfield College, Mile End Road, London El 4NS. Neuropeptide gene expression in sensoryneurones is regulated by the classic neurotrophic factor, nerve growth factor (NGF). | |
| Manolis et al. | 4 Cardiovascular Agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |